Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma

被引:156
作者
Ching, YP
Wong, CM
Chan, SF
Leung, THY
Ng, DCH
Jin, DY [1 ]
Ng, IOL
机构
[1] Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China
[2] Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China
[3] Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China
关键词
D O I
10.1074/jbc.M208310200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hepatocellular carcinoma (HCC) is a major malignancy in many parts of the world, especially in Asia and Africa. Loss of heterozygosity (LOH) on the long arm of chromosome 13 has been reported in HCC. In search of tumor suppressor genes in this region, here we have identified DLC2 (for deleted in liver cancer 2) at 13q12.3 encoding a novel Rho family GTPase-activating protein (GAP). DLC2 mRNA is ubiquitously expressed in normal tissues but was significantly underexpressed in 18% (8/45) of human HCCs. DLC2 is homologous to DLC1, a previously identified tumor suppressor gene at 8p22-p21.3 frequently deleted in HCC. DLC2 encodes a novel protein with a RhoGAP domain, a SAM (sterile alpha motif) domain related to p73/p63, and a lipid-binding StAR-related lipid transfer (START) domain. Biochemical analysis indicates that DLC2 protein has GAP activity specific for small GTPases RhoA and Cdc42. Expression of the GAP domain of DLC2 sufficiently inhibits the Rho-mediated formation of actin stress fibers. Introduction of human DLC2 into mouse fibroblasts suppresses Ras signaling and Ras-induced cellular transformation in a GAP-dependent manner. Taken together, our findings suggest a role for DLC2 in growth suppression and hepatocarcinogenesis.
引用
收藏
页码:10824 / 10830
页数:7
相关论文
共 58 条
  • [31] START: a lipid binding domain in StAR, HD-ZIP and signalling proteins
    Ponting, CP
    Aravind, L
    [J]. TRENDS IN BIOCHEMICAL SCIENCES, 1999, 24 (04) : 130 - 132
  • [32] AN ESSENTIAL ROLE FOR RAC IN RAS TRANSFORMATION
    QIU, RG
    CHEN, J
    KIRN, D
    MCCORMICK, F
    SYMONS, M
    [J]. NATURE, 1995, 374 (6521) : 457 - 459
  • [33] The small GTPases Cdc42Hs, Rac1 and RhoG delineate Raf-independent pathways that cooperate to transform NIH3T3 cells
    Roux, P
    GauthierRouviere, C
    DoucetBrutin, S
    Fort, P
    [J]. CURRENT BIOLOGY, 1997, 7 (09) : 629 - 637
  • [34] RhoA effector mutants reveal distinct effector pathways for cytoskeletal reorganization, SRF activation and transformation
    Sahai, E
    Alberts, AS
    Treisman, R
    [J]. EMBO JOURNAL, 1998, 17 (05) : 1350 - 1361
  • [35] RHO-GTPases and cancer
    Sahai, E
    Marshall, CJ
    [J]. NATURE REVIEWS CANCER, 2002, 2 (02) : 133 - +
  • [36] AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1
    Satoh, S
    Daigo, Y
    Furukawa, Y
    Kato, T
    Miwa, N
    Nishiwaki, T
    Kawasoe, T
    Ishiguro, H
    Fujita, M
    Tokino, T
    Sasaki, Y
    Imaoka, S
    Murata, M
    Shimano, T
    Yamaoka, Y
    Nakamura, Y
    [J]. NATURE GENETICS, 2000, 24 (03) : 245 - 250
  • [37] SCORSONE KA, 1992, CANCER RES, V52, P1635
  • [38] Morphological changes and detachment of adherent cells induced by p122, a GTPase-activating protein for Rho
    Sekimata, M
    Kabuyama, Y
    Emori, Y
    Homma, Y
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (25) : 17757 - 17762
  • [39] SELF AJ, 1995, METHOD ENZYMOL, V256, P67
  • [40] SELF AJ, 1995, METHOD ENZYMOL, V256, P3